Orion Teams Up with Aitia to Advance Cancer Treatments
Orion Corporation has launched an exciting partnership with Aitia, a leader in AI-driven biotechnology. This collaboration aims to revolutionize the way new cancer treatments are discovered and developed, particularly by utilizing Aitia's cutting-edge technology known as Gemini Digital Twins.
The Urgency for New Cancer Treatments
Cancer remains a significant global health crisis that affects millions of individuals each year, putting immense strain on healthcare systems around the world. With nearly 20 million new cases reported recently and countless lives lost, the need for innovative therapeutic solutions in oncology has never been more critical. Projections suggest that this issue may worsen, with cases expected to reach around 35 million annually by 2050, driven by factors such as population growth and aging.
Goals of the Collaboration
This strategic alliance between Orion and Aitia aims to discover and validate new drug targets while developing candidate therapies for various oncological indications. The partnership leverages Aitia's expertise in Digital Twins alongside Orion's deep understanding gained from extensive pre-clinical and clinical research.
Research Rights and Financial Aspects
As part of this agreement, Orion will obtain exclusive rights to conduct research, development, and commercialization for products targeting specific drug targets identified by Aitia. In exchange, Aitia can expect significant upfront payments, along with milestone payments that could surpass USD 10 million for each target, in addition to potential royalties on future sales.
Leadership Perspectives on the Collaboration
Outi Vaarala, the Senior Vice President of Innovative Medicines and Research & Development at Orion, shared her excitement about the collaboration. She highlighted how Aitia’s pioneering technologies would empower Orion to gain deeper insights into biological processes, accelerating the development of new therapies and significantly improving patient outcomes.
Colin Hill, CEO and co-founder of Aitia, echoed her sentiments, underscoring the synergy between their Gemini Digital Twins and Orion’s oncology expertise. Together, they aim to create highly predictive models that could unveil hidden biological mechanisms, propelling the search for effective new drugs.
About Aitia and Orion
Aitia is a trailblazer in AI-powered biotechnology that employs causal AI and creates innovative Gemini Digital Twins to discover groundbreaking drugs in areas like oncology and neurodegenerative diseases. Their methods utilize vast patient data coupled with advanced simulations, ensuring they uncover vital insights that could transform drug development.
Orion Corporation, with a rich history in pharmaceuticals, continues to lead in health solutions, boasting a diverse portfolio that includes both proprietary and generic medications as well as consumer health products. Primarily focusing on oncology and pain management, Orion is dedicated to enhancing pharmaceutical research and development to create effective treatments for conditions including cancer and neurological disorders. Currently, Orion's shares trade on Nasdaq Helsinki, underscoring the company's strong market presence.
Contact Information for Inquiries
For questions about this collaboration or for more details about the company, please reach out to:
Outi Vaarala
Senior Vice President, Innovative Medicines and Research & Development
Orion Corporation
Tel. +358 10 426 3472
Frequently Asked Questions
What is the goal of the Orion and Aitia collaboration?
The collaboration focuses on leveraging AI technologies to boost the discovery and development of new cancer treatments.
What technologies are being used in this partnership?
This partnership utilizes Aitia’s Gemini Digital Twins and Causal AI to enhance the understanding of cancer biology.
How will this collaboration affect the development of cancer treatments?
By pooling their resources, the collaboration aims to speed up the creation of innovative therapies that could lead to improved patient outcomes.
What financial arrangements have been made in this partnership?
Aitia will receive upfront payments and milestone payments that could exceed USD 10 million, along with royalties on the developed products.
Who should be contacted for more information about the partnership?
Outi Vaarala, the Senior Vice President at Orion, is the main point of contact for inquiries regarding this collaboration.
